Benjamin Derman to Multiple Myeloma
This is a "connection" page, showing publications Benjamin Derman has written about Multiple Myeloma.
Connection Strength
17.191
-
Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers. Curr Med Res Opin. 2026 01; 42(1):169-178.
Score: 0.675
-
Clinical applications of mass spectrometry in multiple myeloma. Blood Adv. 2025 Dec 23; 9(24):6593-6603.
Score: 0.667
-
Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time? Hematology Am Soc Hematol Educ Program. 2025 12 05; 2025(1):645-651.
Score: 0.665
-
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy. Drugs. 2025 Oct; 85(10):1231-1251.
Score: 0.654
-
The role of maintenance therapy and its cessation in patients with multiple myeloma. Leuk Lymphoma. 2025 Dec; 66(13):2426-2436.
Score: 0.653
-
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
Score: 0.614
-
Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication. Oncologist. 2024 09 06; 29(9):806-810.
Score: 0.610
-
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 08 29; 144(9):955-963.
Score: 0.609
-
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
Score: 0.599
-
Measurable Residual Disease and Decision-Making in Multiple Myeloma. Hematol Oncol Clin North Am. 2024 04; 38(2):477-495.
Score: 0.582
-
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv. 2023 10 10; 7(19):5703-5712.
Score: 0.573
-
MRD-guided treatment cessation in multiple myeloma. Lancet Haematol. 2023 11; 10(11):e867-e868.
Score: 0.571
-
Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies. Eur J Cancer. 2023 08; 189:112926.
Score: 0.560
-
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Eur J Haematol. 2023 May; 110(5):564-570.
Score: 0.548
-
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
Score: 0.530
-
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. Blood Cancer J. 2022 07 11; 12(7):108.
Score: 0.525
-
Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):e1000-e1008.
Score: 0.525
-
When a Monoclonal Gammopathy Is Not Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-10.
Score: 0.515
-
Knowing the unknowns in high risk multiple myeloma. Blood Rev. 2022 01; 51:100887.
Score: 0.495
-
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021 02 05; 11(2):19.
Score: 0.476
-
Sex differences in outcomes in multiple myeloma. Br J Haematol. 2021 02; 192(3):e66-e69.
Score: 0.469
-
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. J Geriatr Oncol. 2021 05; 12(4):585-591.
Score: 0.468
-
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020 08 07; 10(8):80.
Score: 0.460
-
Clinician attitudes and practices toward measurable residual disease in multiple myeloma. Br J Haematol. 2020 08; 190(3):470-472.
Score: 0.454
-
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Immunother Cancer. 2020 01; 8(1).
Score: 0.441
-
Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma. JCO Precis Oncol. 2026 Jul; 10(7):e2501121.
Score: 0.174
-
Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US. Clin Lymphoma Myeloma Leuk. 2026 Oct; 26(10):e1202-e1210.e8.
Score: 0.174
-
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Sci Transl Med. 2026 May 27; 18(851):eadx1799.
Score: 0.172
-
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1. J Clin Oncol. 2026 Aug; 44(22):e113-e124.
Score: 0.172
-
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Cancer Immunol Res. 2026 Apr 02; 14(4):528-542.
Score: 0.170
-
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial. Lancet Haematol. 2026 Apr; 13(4):e241-e253.
Score: 0.169
-
Diagnosis and Management of Multiple Myeloma With Central Nervous System Involvement. J Natl Compr Canc Netw. 2026 Mar 09; 24(5).
Score: 0.169
-
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline. J Clin Oncol. 2026 04; 44(10):914-941.
Score: 0.167
-
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026 01; 24(1).
Score: 0.167
-
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025. J Natl Compr Canc Netw. 2025 05; 23(5):132-140.
Score: 0.160
-
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. J Appl Lab Med. 2025 Mar 03; 10(2):235-249.
Score: 0.158
-
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma. Leukemia. 2025 04; 39(4):816-826.
Score: 0.157
-
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025 Mar; 39(3):543-554.
Score: 0.157
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024 08; 25(8):e374-e387.
Score: 0.150
-
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone. Pol Arch Intern Med. 2024 05 28; 134(5).
Score: 0.149
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024 05; 25(5):e205-e216.
Score: 0.149
-
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial. Br J Haematol. 2023 12; 203(5):792-802.
Score: 0.142
-
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 02; 24(2):139-150.
Score: 0.136
-
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma. J Hematol Oncol. 2022 08 16; 15(1):106.
Score: 0.132
-
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523.
Score: 0.117
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 01; 35(1):18-30.
Score: 0.115